Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Debt (2020 - 2026)

ImmunityBio has reported Non-Current Debt over the past 6 years, most recently at $324.6 million for Q4 2025.

  • Quarterly Non-Current Debt rose 14.14% to $324.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $324.6 million through Dec 2025, up 14.14% year-over-year, with the annual reading at $324.6 million for FY2025, 14.14% up from the prior year.
  • Non-Current Debt was $324.6 million for Q4 2025 at ImmunityBio, up from $316.1 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $480.0 million in Q3 2023 and troughed at $111.1 million in Q3 2024.
  • The 5-year median for Non-Current Debt is $300.3 million (2021), against an average of $284.9 million.
  • Year-over-year, Non-Current Debt surged 506.48% in 2021 and then tumbled 76.85% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $303.2 million in 2021, then increased by 23.1% to $373.3 million in 2022, then crashed by 58.37% to $155.4 million in 2023, then surged by 83.0% to $284.4 million in 2024, then increased by 14.14% to $324.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Non-Current Debt are $324.6 million (Q4 2025), $316.1 million (Q3 2025), and $307.0 million (Q2 2025).